MediPharm Labs Corp. (TSX:LABS)
Canada
· Delayed Price · Currency is CAD | Market Cap | 38.24M |
| Revenue (ttm) | 45.12M |
| Net Income (ttm) | -8.27M |
| Shares Out | 424.86M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,691,917 |
| Average Volume | 509,979 |
| Open | 0.0800 |
| Previous Close | 0.0750 |
| Day's Range | 0.0800 - 0.1000 |
| 52-Week Range | 0.0600 - 0.1100 |
| Beta | 0.87 |
| RSI | 75.80 |
| Earnings Date | May 14, 2026 |
About MediPharm Labs
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, develops, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll canna... [Read more]
Financial Performance
In 2025, MediPharm Labs's revenue was 45.12 million, an increase of 7.54% compared to the previous year's 41.96 million. Losses were -8.27 million, -22.69% less than in 2024.
Financial StatementsNews
MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling
On April 22, 2026, the U.S. Department of Justice and Drug Enforcement Administration's final order rescheduling FDA-approved cannabis drug products and state-licensed medical cannabis from Schedule I...
MediPharm Labs Earnings Call Transcript: Q4 2025
Full-year revenue grew 8% to CAD 45 million, led by a 42% increase in international medical cannabis, now over half of total revenue. Gross margin improved to 31%, and net loss narrowed to CAD 8.3 million. Strong balance sheet, no material debt, and continued focus on international growth.
MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue
FY 2025 revenue of $45.1 million, an increase of 8% over 2024 International Medical Cannabis revenue increased 43% year-over-year and represented more than 50% of total revenue Increased cash balance ...
MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results
MediPharm Labs will release its financial results for the three & twelve months ended December 31st, 2025, before markets open on Monday, March 30th, 2026.
MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO
TORONTO, Jan. 19, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoi...
MediPharm Labs to Enter New Market with Costa Rica Supply Agreement
TORONTO, Jan. 13, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specialized in precisio...
Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience
TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision...
MediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby Returns
TORONTO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoi...
MediPharm Labs Completes First Shipment to France
TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precisio...
MediPharm Announces Complete Dismissal of Defamation Action Initiated by Apollo, Nobul and Regan McGee Under Ontario Anti-SLAPP Law
TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoi...
MediPharm Labs Earnings Call Transcript: Q3 2025
Q3 2025 saw 17% revenue growth year-over-year, led by an 83% increase in international medical cannabis sales, now 56% of total revenue. Gross margin declined to 22% due to product mix and plant shutdowns, but management expects improvement as new higher-margin products and markets ramp up.
MediPharm Advances Global Reach in Q3 2025 with Double-Digit Revenue Growth and Strong International Medical Cannabis Gains
Q3 2025 Revenue of $11.4 Million, an Increase of 17% over Q3 2024 83% Growth in Year-Over-Year Revenue for International Medical Cannabis International Medical sales now 56% of Total Revenue Increased...
MediPharm Labs Sets Date to Report Third Quarter 2025 Financial Results
TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precisi...
/U P D A T E -- MediPharm Labs Corp./
In the news release, MediPharm Labs Raises Concerns About Poorly Qualified Dissident Nominees, issued 15-May-2025 by MediPharm Labs Corp. over PR Newswire, please be advised that updates have been mad...
MediPharm Labs Earnings Call Transcript: Q2 2025
Q2 2025 saw 14% revenue growth year-over-year, led by a 50% surge in international medical cannabis sales, now 57% of total revenue. Gross margin was 28%, with adjusted EBITDA at -$0.6 million. The company remains debt-free, cash-rich, and focused on global expansion and innovation.
MediPharm Strengthens Global Position in Q2 2025, with 14% Revenue Growth and 50% Increase in International Medical Cannabis
Q2 Revenue of $11.8 Million, an Increase of 14% over Q2 2024 50% Growth in Revenue for International Medical Cannabis International Medical sales now 57% of Total Revenue Cash Balance of $10.4 Million...
MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States
MediPharm Labs holds unique US Food and Drug Administration (FDA) site registration in relation to the manufacturing and release of pharmaceutical cannabis products. MediPharm is the only US FDA Aud...
MediPharm Labs Sets Date to Report Second Quarter 2025 Financial Results
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precisi...
MediPharm Labs Expands Leading CBN Oil Portfolio with The Launch of New Nighttime Inhaler
TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specializing in precisi...
MediPharm Announces Voting Results from the 2025 Annual and Special Meeting of Shareholders
TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoi...
MediPharm Cautions Shareholders To Await Final Results of Annual and Special Meeting
TORONTO, June 16, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoi...
Apollo Capital Wins Proxy Contest at MediPharm Labs
MediPharm Labs' Board's Material and Unprecedented Breaches of Securities Laws Are Part of Their Undoing
Leading Independent Proxy Advisor Glass Lewis Recommends Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees
TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoi...
MediPharm Reminds Shareholders to Vote in Advance of June 13 Deadline
TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm,” the “Company,” “we” or “us”), a pharmaceutical company specialized in precision-base...
MediPharm Announces Complete Dismissal of Dissident Court Proceeding Related to Annual and Special Meeting
TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoi...